Clinical Trials

Multiple clinical trials evaluate ferrous fumarate across diverse settings, focusing on iron deficiency, iron absorption following Roux-en-Y gastric bypass, and preoperative hemoglobin optimization in craniosynostosis patients. Encompassing Phase 4 studies along with non-phased observational and interventional protocols, these trials are sponsored by academic and hospital centers, including University Hospital Montpellier, Rijnstate Hospital, and Baylor College of Medicine. These investigations maintain statuses ranging from completed to active recruitment.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03231085 Recruiting
Craniosynostosis
University Hospital Montpellier
2017-10-31 Not Applicable
NCT02228902 Completed
Iron Absorption|Bariatric Surgery|Roux- en -y Gastric Bypass
Rijnstate Hospital
2014-08 Phase 4
NCT00570895 Completed
Iron Deficiency
Baylor College of Medicine
2008-01 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ferrous fumarate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ferrous fumarate dissociates to supply bioavailable ferrous iron ions that incorporate into protoporphyrin IX within erythroid precursor cells, enabling functional heme assembly and proper hemoglobin production for cellular oxygen delivery. By enhancing hemoglobin synthesis and restoring functional iron reserves, this process effectively ameliorates systemic iron deficiency and supports patient management in clinical settings such as post-bariatric iron malabsorption and preoperative anemia correction.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.